How policymakers value end-of-life treatments for rare and common diseases in China: evidence from a contingent valuation study
{{output}}
Background: Understanding policymakers' value judgements in reimbursement decisions is essential for promoting equity and guiding informed healthcare decision-making. This study aimed to estimate and compare Chinese policymakers... ...
